DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01619345

CompletedPhase 1

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

27

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18.5-30•Male

Primary endpoint

•Anatomical location of tablet at complete tablet erosion (CTE)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01619345
Org study IDNN9924-3957
Secondary ID2011-004162-14
Secondary IDU1111-1123-7450WHO

Timeline

Milestones

Study first posted2012-06-14estimated
Last update posted2015-02-23estimated
Study start2012-06 (month precision)
Primary completion2012-08actual (month precision)
Study completion2012-08actual (month precision)

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age64 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Good general health
•Body mass index (BMI) of 18.5-30.0 kg/m^2 (both inclusive)

Exclusion criteria

•Males who are not willing to use two acceptable forms of highly effective contraception
•Participation in another clinical trial within 90 days
•Any chronic disorder or severe disease
•Use of GLP-1 (glucagon-like peptide-1) agonists within 3 months preceding dosing
•Subjects who are smokers
•Subjects who have donated any blood or plasma in the past month or in excess of 500 mL within the 12 weeks preceding screening

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
3
Safety / tolerability / PK
2

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint

Area under the NN9924 concentration curve

Time frame:From time 0-24 hours

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint/low confidence

Time to ITE

Time frame:Assessed 0-4 hours post dose

descriptive

Other (unclassified)

3 endpoints
Primary/protocol endpoint/low confidence

Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE)

Time frame:Assessed 0-4 hours post dose

descriptive

Secondary/protocol endpoint/low confidence

Anatomical location of initial tablet erosion (ITE)

Time frame:Assessed 0-4 hours post dose

descriptive

Secondary/protocol endpoint/low confidence

Time to CTE

Time frame:Assessed 0-4 hours post dose

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.